| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Syros Pharmaceuticals, Inc.$0
+0 (+100%)
D 35Pipeline Score Fair Value Biotech · Clinical
Market Cap
3.14 M
EPS
-3.03
P/E Ratio
-
Value Trade
4.29
SEC Financials
Q3 2024Dilution Risk
R&D Expenses
20.53 M
Total Assets
85.00 M
Total Liabilities
85.00 M
Equity
-11.12 M
11.62 %
Week
-36.65 %
1 Month
-44.19 %
3 Month
-93.99 %
6 Month
-99.79 %
5 Year
-99.92 %
All Time
Cash Data
Cash Position
58.27 M
Monthly Burn
8.73 M
Runway
0 mo
Burn Trend
StableSEC Filing
Oct 31, 2024
Overview
Volume
14.21 K
52 Week Range
0.16 - 7.96
% held by Insiders
0.01 %
% held by Institutions
0.26 %
Enterprise Value
6.92 M
Total Shares
26.83 M
Short %
0.03 %
Float Shares
23.92 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-11-15 | Tamibarotene | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-11-15 | Tamibarotene | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-11-15 | Tamibarotene | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D35
Pipeline Score $3M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored0.9x
rNPV / MCap Top 49%
Micro Cap (rank 472 of 923)
Percentile RankSyros Pharmaceuticals, Inc. faces pipeline headwinds (35/100), with $4.4B risk-adjusted pipeline value, led by SY-5609 in Advanced Solid Tumor (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SY-5609 Small molecule | Advanced Solid Tumor | Phase 1 | NCT04247126 | 5% | $4.2B | COMPLETED | 105 | - | - | Mar 30, 2023 | - | Oct 27, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CTX001 | sickle cell disease and beta thalassemia | — | 2020-12-07 | 10 patients treated with CTX001, which demonstrated a consistent and sustained response Read More | ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope Read More | |
CTX001 | sickle cell disease and beta thalassemia | — | 2020-12-07 | 10 patients treated with CTX001, which demonstrated a consistent and sustained response Read More | ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope Read More | |
CTX001 | sickle cell disease and beta thalassemia | — | 2020-12-07 | 10 patients treated with CTX001, which demonstrated a consistent and sustained response Read More | ASH 2020: CRISPR and Vertex’s Potential Cure for Sickle Cell Disease and More Glimmers of Hope Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SYRS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SYRS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How SYRS ranks across every disease it competes inCompetitive Position is a premium feature
See how SYRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial